Particles in the size-range of one to 100 nanometres called nanoparticles exhibit significantly different physical and chemical properties owing to their large surface area to volume ratio. Nanoparticles are finding new applications in medicine. They can combine diagnosis and delivery into one device. This allows precise treatment and more personalized medicine. Preclinical studies on rats show nontoxic poly graphene nanoribbons (GNRs) generate an environment for spinal cord recovery after injury, and greatly improve in movement.
In this Expert Exchange, Megan Muroski, Senior Product Manager at MilliporeSigma, the US and Canada Life Science business of Merck KGaA, Darmstadt, Germany, discusses the application of nanoparticles and nanoribbons in treating spinal cord injury and their application as diagnostic tools and delivery vehicles in precision medicine. She discusses the synthesis of nanomaterials, their use in detecting biomolecules, their chemical modification for desirable attributes and evolving regulatory protocols for nanotechnology. Megan has extensive experience in leading and managing a broad range of global projects and programs in fstrategic business, corporate, and technology initiatives in the life sciences industry. She is a biochemist with 10+ years combined experience in academic, pre-clinical/translational, and government laboratories at Florida State University, Northwestern, and the US Naval Research Lab (DARPA). She has a multi-disciplinary background in nanoparticles and their applications in neuroscience, biotechnology, translational studies, drug delivery, sensors, and oncology.